Posted: June 2017 By Νiki Karachaliou, MD, PhD The identification of oncogenic driver alterations in non-small cell lung cancer (NSCLC), such as EGFR mutations and ALK rearrangements, each of which […] Read more

Posted: April 2017 By Keightley Amen, BA, ELS To help ensure that high-quality thoracic oncology care is available throughout the world and well into the future, the IASLC offers an […] Read more

Posted: April 2017 By Cynthia L. Kryder, MS, CCC-Sp, with Ramón Rami-Porta, MD Clinicians around the world began implementing the 8th edition of the tumor, node, and metastasis (TNM) classification […] Read more

Posted: February 2017 By Chee-Keong Toh, MD, and Daniel SW Tan, MD The recent decade has seen much interest in lung cancer in never-smokers (LCNS), in most part attributed to […] Read more

By Julien Mazières, MD, PhD, and Julie Milia, PhD Once considered a “man’s disease,” lung cancer no longer discriminates. During the last decade, lung cancer in women has become the […] Read more

By Jyoti Malhotra, MD, MPH and Paolo Boffetta, MD, MPH Lung cancer is the most frequent malignant neoplasm in most countries worldwide, and the main cause of cancer death in […] Read more

Posted: November 1, 2016 How one investigator’s passion and devotion to science led to discovery of the “ghost gene” in MPM Q&A with Michele Carbone, MD Q: Many laboratories are […] Read more

By Cynthia L. Kryder, MS IASLC Lung Cancer News recently spoke with Kapil Dhingra, MD, of KAPital Consulting LLC in Sparta, New Jersey, about oncologic drug development and the challenges […] Read more

Next-generation sequencing (NGS) technology has revolutionized genomic and genetic research as it fulfills its potential to tailor the treatment of cancer patients in general and non-small cell lung cancer (NSCLC) […] Read more

By Adi F. Gazdar, MD While all of the major histological forms of lung cancer are strongly associated with smoking, an important subset (about 20% worldwide, 10–15% in the US) […] Read more